Skip to content
BiologicalX

Comparison

GHK-Cu vs Magnesium L-Threonate

Side-by-side of GHK-Cu and Magnesium L-Threonate. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

GHK-Cu

  • Endogenous tripeptide that binds copper(II); plasma levels decline ~60% from age 20 to 60
  • Topical RCTs show improvement in skin firmness, fine lines, and barrier function over 12 weeks
  • Wound-healing models report accelerated re-epithelialization in diabetic and aged skin
  • Pickart gene-expression analyses show reset of >4000 genes toward a younger expression profile in cell culture
  • Anecdotal subcutaneous longevity protocols use 1 to 3 mg daily; no human longevity RCTs exist
  • Hair-growth claims rest on small open-label trials and topical scalp formulations

Magnesium L-Threonate

  • Distinct magnesium salt designed for blood-brain barrier penetration; not a higher-quality systemic magnesium
  • Liu 2010 rodent study: elevated CSF magnesium ~15% and increased hippocampal synaptic density
  • Trial portfolio in humans is small and mostly Magtein-funded; cognitive effects are modest where reported
  • Typical dose 1500 to 2000 mg/day delivers only ~108 to 144 mg of elemental magnesium
  • GI tolerability comparable to other magnesium forms; loose stools in a minority at 2000 mg/day
  • Distinct from magnesium glycinate, which is the conventional sleep/anxiety/repletion form

Side-by-side

Attribute GHK-Cu Magnesium L-Threonate
Category peptide supplement
Also known as Copper Peptide, Glycyl-L-histidyl-L-lysine copper, GHK Mg-T, MgT, Magtein, magnesium threonate
Half-life (hr) 0.5 4
Typical dose (mg) 2 2000
Dosing frequency daily 1 to 3 times daily
Routes topical, subcutaneous oral
Onset (hr) 24 1
Peak (hr) 168 2
Molecular weight 340.85 294.5
Molecular formula C14H24N6O4 (GHK alone); C14H22CuN6O4 with Cu(II) C8H14MgO10
Mechanism Tripeptide that chelates Cu(II) and delivers it to copper-dependent enzymes (lysyl oxidase, superoxide dismutase). Modulates expression of >4000 genes toward a younger profile in fibroblast culture, including upregulation of decorin and downregulation of pro-inflammatory cytokines. Proposed to deliver magnesium across the blood-brain barrier more effectively than other oral salts via threonate-related transporters, raising CNS magnesium and modulating NMDA receptor function and synaptic plasticity.
Legal status Topical cosmetics legal in most jurisdictions; injectable form not FDA approved for any indication; research-use-only grey market OTC dietary supplement
WADA status allowed allowed
DEA / Rx Topical OTC (cosmetic); injectable not FDA approved; research-chemical status OTC supplement (not scheduled)
Pregnancy Insufficient data; topical use likely low-risk; injectable not recommended Standard magnesium safety; Mg-T-specific data limited
CAS 49557-75-7 778571-57-6
PubChem CID 73587 10691810
Wikidata Q3104638 Q27151568

Safety profile

GHK-Cu

Common side effects

  • mild erythema at topical site
  • transient itch
  • blue-green discoloration of injection site (copper)
  • rare contact dermatitis

Contraindications

  • copper allergy
  • Wilson disease
  • open wound near injection site (caution)
  • pregnancy (no data)

Interactions

  • topical retinoids: additive irritation; alternate days or apply at different times(minor)
  • topical vitamin C (ascorbic acid): ascorbate reduces Cu(II) to Cu(I), which can destabilize the GHK-Cu complex; separate by 30 minutes(minor)

Magnesium L-Threonate

Common side effects

  • loose stools
  • mild GI upset
  • headache (rare)
  • fatigue (rare)

Contraindications

  • severe renal impairment (eGFR below 30)
  • hypermagnesemia
  • myasthenia gravis (high doses)
  • concurrent IV magnesium therapy

Interactions

  • tetracyclines and fluoroquinolones: magnesium chelation reduces antibiotic absorption; separate by 2 to 4 hours(moderate)
  • bisphosphonates: reduced absorption; separate by 2 hours minimum(moderate)
  • muscle relaxants and aminoglycosides: potentiated neuromuscular blockade at high doses(moderate)
  • antihypertensives: additive blood pressure reduction at high doses(minor)

Which Should You Take?

Magnesium L-Threonate comes out ahead for most readers on the criteria we weight: 2 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. GHK-Cu is the right call when one of the conditionals below applies.

Edge case: If you want to avoid research-only / gray-market sourcing, Magnesium L-Threonate is the more accessible choice.

Default choice: Magnesium L-Threonate. Lower friction to source, and broader goal coverage. Reach for GHK-Cu only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between GHK-Cu and Magnesium L-Threonate?

GHK-Cu and Magnesium L-Threonate differ in category (peptide vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, GHK-Cu or Magnesium L-Threonate?

GHK-Cu half-life is 0.5 hours; Magnesium L-Threonate half-life is 4 hours.

Can you stack GHK-Cu with Magnesium L-Threonate?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper